You do not have permission to access this chart.
Please Sign Up or Login

About:

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

65

Address:

Midatech Pharma plc Oddfellows House 19 Newport Road Cardiff CF24 0AA United Kingdom

Website:

http://www.midatechpharma.com

Phone:

44 1235 888 300

Leave a comment

Your email address will not be published. Required fields are marked *